Background Cardiovascular disease (CVD) in insulin dependent diabetes mellitus (IDDM) 
explore these findings, and to determine if the CVD rates and risk factor associations are similar in the US and in Europe, this report compares the prevalence of CVD in these two studies.
Subjects, Materials and Methods

Study population
For the purposes of this report, comparable populations were identified from the EDC and the EURODIAB IDDM Complications Study by including only those with IDDM diagnosed before the age of 17 and only those with durations of diabetes >6 years at the time of the study. Similarly, to achieve comparability by age, only those > 15 years were included.
The EDC population has been previously described elsewhere. 5 -6 Briefly, the EDC is a prospective investigation of the development of diabetes complications in a US population of childhood onset EDDM subjects. All subjects were originally part of a 1950-1980 registry of IDDM patients at the Children's Hospital of Pittsburgh, which included all those diagnosed with IDDM before the age of 17 (mean age at onset = 8.5 years), and seen at the hospital within one year of diagnosis. When recruited into the EDC Study in 1986-1988, the minimum age and duration of diabetes was 6 years, with a maximum age of 54 years and duration of 38 years. At entry to the study, subjects were mailed questionnaires and invited to attend the research centre for a full clinical examination, including assessment for the presence of each of the major diabetic complications. A resting 12-lead ECG was also recorded. Subjects also collected three timed urine samples: an overnight, a 24-hour, and a 4-hour clinic sample. Participants continue to be followed up every 2 years after their baseline exam.
Full details of the EURODIAB IDDM Complications Study methodology have also been published elsewhere. 7 Subjects were seen between 1988 and 1990. Insulin dependent diabetes mellitus was defined as diabetes diagnosed before age 36 (mean age at onset = 10.2 years) with a continuous need for insulin from within one year after diagnosis. The EURODIAB study population consists of 31 stratified random samples of clinic IDDM patients aged 15-60 years. Patients were stratified by sex, age (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) , and 45-60 years), and duration of disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and ^15 years). Each centre's investigators followed standardized procedures to assess the presence of IDDM complications. Albumin excretion rates were calculated from a timed 24-hour urine collection measured in a single laboratory.
In both studies, the prevalence of CVD was determined by a past history or the presence of electrocardiogram (ECG) abnormalities. The patients were asked if they had ever been told by a doctor that they have had a heart attack, angina pectoris, stroke, or a coronary artery bypass graft. The ECGs from both studies were classified by the same two observers according to the Minnesota Code. 8 Any discrepancies between the two observers were adjudicated by a third. The ECG abnormalities suggestive of probable ischaemia consist of codes 1.1 and 1.2 (major Q/QS waves) and code 7.1 (complete left bundle branch block). Possible ischaemia consists of code 1.3 (minor Q waves); codes 4.1, 4.2, and 4.3 (S-T segment abnormalities); and codes 5.1, 5.2, and 5.3 (T wave abnormalities). Cardiovascular disease was considered to be present if the patients answered positively to any of the above questions or had an abnormal ECG finding suggestive of probable or possible ischaemia.
In both studies, blood pressure (BP) was determined using the Hawksley random zero sphygmomanometer after training and testing of local investigators in the measurement technique. Diastolic pressure was recorded at the disappearance of sound (phase V). The average of two consecutive blood pressure measurements was calculated. The use of antihypertensive medication was recorded. The presence of hypertension was defined as systolic BP »140, diastolic BP s«90, or use of anti-hypertensive medication. Height and weight were measured using a stadiometer and calibrated beam balance where possible. Heavy outer garments and shoes were removed before measuring height and weight. Body mass index (BMI) was calculated. Waist rircumference was defined at the midway level between the costal margins and the iliac crests in both studies. Hip circumference was measured at the level of the greater rrochanters in EURO-DIAB (if not palpable, the largest gluteal circumference was recorded), while in EDC the maximal hip girth was recorded and the waist-to-hip ratio was calculated.
A venous blood sample was taken from all subjects for the measurement of plasma lipids in both studies (triglycerides, cholesterol, HDL cholesterol) and blood HbA lc (EURODIAB) or HbAj (EDC). Blood was collected in EDTA tubes after an overnight fast and before the morning insulin injection. Of the EURODIAB centres, eight elected to collect non-fasting blood samples; in subsequent analysis of triglycerides, these centres are not included. Plasma was separated by centrifugation at 1500 g for 10 min at ambient temperature. Aliquots of whole blood, plasma, and urine were stored at -40°C at each centre until transported to the central laboratory on solid carbon dioxide. On receipt, samples were kept at -20°C until analysed. In EDC, samples were handled in a similar fashion but lipids were run within 2-4 weeks.
In EURODIAB, the triglyceride 9 and cholesterol 10 concentrations of plasma and the cholesterol concentration of HDL 1! were assayed by standard enzymatic methods (Boehringer Mannheim, East Sussex, UK) using a cobas-bio centrifugal analyser (Roche, Welwyn Garden City, Herts, UK). For HDL cholesterol, samples with triglyceride concentrations >3 mmol/1 were diluted with 0.15 mol/1 sodium chloride solution before chemical precipitation. In EDC, total cholesterol and triglycerides were measured enzymatically. 912 The HDL cholesterol was determined by a precipitation technique with a modification 1! of the Lipid Research Clinic's method. 13 Low density lipoprotein (LDL) cholesterol concentration was calculated from the formula by Friedewaldrta/. 14 In the EDC study, GHb (stable levels of total HbAj) was originally measured with saline-incubated blood samples and micro-column cation-exchange chromatography (Isolab, Akron, OH). In October 1987, the GHb technique was changed to high-performance liquid chromatography (Diamat, Bio-Rad, Hercules, CA), with no systematic differences observed when duplicate samples were run (r = 0.95, with an absolute difference of 0.158, % HbAi). The normal range for this measure of GHb is <7.4%. For EURODIAB, HbA lc was measured in a central laboratory by an enzyme immunoassay using a monoclonal antibody raided against HbA, c (Dako, Ely, UK), the normal range being <4.9%. A consecutive series of blood samples (n = 25) was taken from the EDC and measured by the EURODIAB study group. Results showed a high correlation (r = 0.95; P < 0.001) between the two sets of measurements. Fibrinogen was measured by a buiret colorimetric procedure and a dotting method in EDC and by a clotting assay based on prothrombin time in EURODIAB.
Microalbuminuria was defined as an albumin excretion rate between 20 and 200 ng/min. Macroalbuminuria was defined as an albumin excretion rate >200 ng/min. These limits were applied to the single 24-hour collection in the EURODIAB study, while for the EDC, two out of three samples (24-hour, overnight, and/or 4-hour clinic) had to be positive. In EDC, urine collections were validated by creatinine excretion. When a classification could not be made on the basis of two valid collections, a previously validated albumin creatinine ratio from the pre-clinic spot urine was used. Urine collections were not validated in EURODIAB. To ensure that these classification differences did not affea the results, key findings were repeated using only the 24-hour samples from EDC (n = 540). Similar or somewhat stronger results were seen. In EDC, 91% of subjects were identically identified by both the 24-hour sample alone and the two-out-of-three method. The methodology and comparability of urinary albumin measures in the two studies have been previously described. 15 A blinded stratified sample (n = 24) of urine (with equal proportions of urine samples taken from normoalbuminuric, microalbuminuric, and macroalbuminuric patients) was taken from the EDC centre to be measured by the EURODIAB study research team. Analysis demonstrated a high correlation (r = 0.98; P < 0.0001) between the measurements of the samples taken by the two centres. 15 Possible differences in classification of albuminuria (i.e. normo-, micro-, and macroalbuminuria) were also examined using equivalent albumin concentrations. Using >19 mg/1 as the cutoff for microalbuminuria and >192 mg/1 for macroalbuminuria, we found 100% agreement for determining normoalbuminuria versus micro-/macroalbuminuria and 71% agreement for macroalbuminuria alone (of the seven found to be overt by EDC, five were also found to be overt by EURODIAB).
15
Statistical analysis
To assess differences in risk factors for patients with and without CVD, for continuous variables, least squares regression was used to calculate age-adjusted means. The adjusted means were the predicted values when age was held at the mean value for the whole sample. For categorical variables, percentages were directly standardized to the age distribution of the whole sample and the extended Mantel-Haenszel x 2 used to test for significant differences. In order to assess variables most explanatory of CVD, forward stepwise logistic regression was performed for each study separately, with CVD was the dependent variable and significant univariate correlates as potential explanatory variables. The criterion for a variable to enter the model was P < 0.05. This multivariate analysis was performed with and without macroalbuminuria included as a potential explanatory variable.
Results
The gender-specific prevalences of CVD in the EURODIAB and EDC populations are shown in Table 1 . The proportions of males and females were almost equal in both populations. Although the mean age of both the EURODIAB and EDC subjects was 28 years, a greater proportion of EDC participants were *30 years of age (? < 0.001). This age distribution was similar between genders in both populations. The duration of BDDM was also longer in EDC than in EURODIAB. In general, the prevalence of CVD did not differ significantly between EURODIAB and EDC, except for angina in females (0.5 versus 3.9, respectively, P < 0.001). EURODIAB women showed a marginally greater prevalence of abnormal ECGs. Myocardial infarction, stroke and all CVD events were remarkably similar for EURODIAB and EDC subjects for both male and female.
The age-adjusted risk factors for CVD in both populations are shown in Tables 2a and 2b . Males and females with CVD were significantly older than those without CVD in both populations 18.9(8.6) 19.9 (7.5) " Electrocardiogram. * P < 0.001 for the rate difference between EURODIAB females and EDC females. •140 or anrihypertension therapy. (Tables 2a and 2b ). Higher triglycerides and lower HDL cholesterols were also seen (in both populations) for male subjects with CVD, although the triglyceride difference was only significant for EDC subjects while the HDL cholesterol was only significant in EURODLAB. Low density lipoprotein cholesterol was only a risk factor in EDC men, while HbAj was marginally higher for those with CVD in both male groups. EURODLAB women with CVD had a lower level of HbA lc , unlike EDC women where the cases had higher HbAj (Table  2b ). Lipids and lipoproteins were not increased in CVD positive subjects in either female population although fibrinogen levels were increased in EDC women.
Hypertension and macroalbuminuria were associated with CVD in both male populations. Smoking history was generally, but weakly, increased in male CVD subjects although significance was only seen in EURODLAB subjects for a past history of smoking. In women, however, the renal and hypertension differences noted in men were less evident, while EURODLAB women with CVD were less likely to be current smokers. Cardiovascular disease is significantly higher in EDC women with microalbuminuria.
Since we have previously noted that macroalbuminuria was more prevalent in the EDC population, 15 cardiovascular disease prevalence was further examined after stratification by degree of albuminuria. Figure 1 shows prevalence of CVD by three categories of renal function (normal, microalbuminuria, and macroalbuminuria). As can be seen, for men in both EURODLAB and EDC populations and for EDC women, an approximate fivefold increased prevalence of CVD is seen in those with macroalbuminuria compared to those with normal AER (P = 0.000, 0.077 and 0.000 respectively). However, EURODLAB women show a weaker relationship {P = 0.114). Also apparent from Figure 1 is the consistent, but small, excess of CVD in EURODLAB men compared to EDC men, however, this only approaches significance (P = 0.09) for microalbuminuria. The pattern is very different for women while for those with normal albumin excretion, EURODIAB subjects showed a marked excess (P = 0.02); with more severe nephropathy, EDC subjects show a modest excess.
To evaluate the independent association between risk factors and CVD, multivariate analyses were conducted in each population. Significant univariate risk factors in Table 2 were available to the model in a stepwise mode. Nephropathy was unavailable to enter into the model in two ways: as macroalbuminuria and as any nephropathy (microalbuminuria and macroalbuminuria combined). Age and HDL cholesterol were independent predictors in EURODIAB men, while for EDC triglycerides and hypertension were predictors. Nephropathy did not enter either model.
For women, age and hypertension predicted CVD in EURO-DIAB, and age and macroalbuminuria in EDC. Strikingly, GHb predicted CVD in both populations but in opposite directionsa positive relationship in EDC and a negative association in EURODIAB. The EURODIAB data was further examined to see if the inverse association was limited to any particular CVD entity. For each component (MI, ECG, etc.), HbA lc was at least 0.4% lower in those affected. The distribution of CVD events in EURODIAB women was also examined by quartile of GHb revealing per cent prevalence from low to high of 15%, 7%, 3% and 6%. The dear concentration of cases (n = 19) in the bottom quartile was further explored. In this subgroup of EURODLAB women, triglycerides and hypertension were (unlike overall) significant CVD risk factors (P = 0.04, 0.0002 respectively) providing some explanation for the high rates although smoking was again less frequent in those with CVD (P = 0.06). These cases did not come from any particular cluster of centres, indeed 12 of the 19 centres with women who have CVD are represented.
Discussion
This report confirms the high prevalence of CVD in IDDM subjects and suggests that event rates are similar in the two continents. It should be noted, however, that these are cross-sectional data and while the EDC population is a fairly representative cohort from the Pittsburgh area, 16 the larger EURODIAB population is derived from hospital clinics in 31 centres throughout Europe. 7 The prevalence of CVD in the total EURODIAB IDDM population (which was older than the subjects studied here) ranged from 3% to 19% with an overall prevalence of 9% in men and 10% in women.
Another important observation that these data confirm is the loss of the gender difference such that women with IDDM have similar rates to men. First reported in terms of CVTJ mortality in the Allegheny County data, 17 this observation has been subsequently confirmed in later Pittsburgh data 4 as well as data from the Joslin 18 and Steno 2 clinics. This loss of a female protection also seen in NTDDM in terms of fatal CHD but not morbidity, e.g. prevalent ML 19 has led to speculation that either the female protective factor is absent, or dramatically altered, in IDDM, e.g. a better insulin sensitivity in women 20 or that a new overriding factor obliterates the gender effect. One potential candidate for the latter effect might be renal disease, which the Steno clinic clearly showed to be a major risk factor for CHD in IDDM. 2 This observation has been confirmed by WHO data 21 and data from Pittsburgh where, using prospective data from the same study (EDC) used in this comparison, the effect was seen to be approximately twice as great in men as in women, but did not improve the overall prediction beyond the effects of blood pressure and lipid disturbance. 4 More recent data from Steno also suggests that even slightly elevated urinary albumin predicts atherosclerotic vascular disease in IDDM.
The current comparison provides a valuable way to explore further the renal link. In neither population did renal disease (whether determined by the presence of macroalbuminuria alone or in combination with microalbuminuria) enter the male final multivariate models, again suggesting that in Europe, as in Pittsburgh, the renal effect is effectively mediated through lipid and BP disturbance. Furthermore, as we have previously reported, 15 overt renal disease is twice as high in the EDC population as in the EURODIAB population. One might, therefore, anticipate that CVD rates would be similarly increased in EDC. This is not the case. Indeed, there is a general trend for CVD rates to be a little higher in EURODIAB men than in EDC men (irrespective of renal status) while in women, the same is true (and reaches significance) for normoalbuminuric women. However, the presence of renal disease does not seem to have much effect on CVD rates in EURODIAB women, while in the EDC women, the usual pattern is observed. In summary, despite an increased prevalence of renal disease in EDC, CVD rates are similar, partly reflecting a higher female rate, in EURO-DIAB women without renal disease. The renal contribution in both studies is accounted for statistically by other associated risk factors at least in men, and EURODIAB women.
Consideration of the CVD risk factors operating in both populations provides many similarities and one major difference. Age is dearly important and enters three of the four multivariate models. Even in EDC where it did not remain in the final model for men, the mean univariate difference was of a similar magnitude to that seen in EURODIAB (5.1 versus 6.0 years respectfully), and was greater than the (independent) difference in EDC women (4.1 years). It, thus, seems likely that the failure of age to be independent reflects its high correlation with hypertension (r = 0.4, P < 0.0001). Duration of diabetes is not a significant predictor. However, because of the high correlation between age and duration in both EDC and EURODIAB (0.76 and 0.89 respectively), we are unable to fully address this issue. Smoking does not appear to relate to CVD prevalence in either study population.
Lipid and lipoprotein concentrations surprisingly provide little prediction in women in either population, similar to the Pittsburgh prospective data, 4 while in men, HDL cholesterol and triglycerides are predictive with the former predominating in EURODIAB and the latter in EDC. Low density lipoprotein cholesterol showed no relationship in EURODIAB, but a significant relationship was seen in EDC. Lipid and lipoprotein concentrations cannot, therefore, explain the marginally increased event rates in EURODIAB, especially in normoalbuminuric women. Twenty-six samples were exchanged for lipid determinations and high correlations found (total and HDL cholesterol, triglycerides r = 0.96, 0.95, 0.92 respectively). Using the derived regression equations, marginally lower mean values were noted in EURODIAB for both cholesterol and triglycerides, although HDL cholesterols were also a little lower in EURODIAB subjects (i.e. mean HDL cholesterol in men without CVD in EURODIAB was 1.23 versus 1.27 mmol/1 in EDC while in women, 1.42 versus 1.53 mmol/1 respectively). Thus, the populations showed essentially similar lipid profiles.
Hypertension is dearly a major risk factor in both populations, and contributes in the final model for EDC men and EURODIAB women. It is also likely to be a major contributor to the prediction of CVD by macroalbuminuria in EDC women as previous analyses have shown that BP and macroalbuminuria are equivalent and alternate CVD predictors in EDC. The lack of entry of hypertension to the male EURODIAB model is likely to be purely mathematical for it is a strong univariate predictor. Interestingly, although the prevalence of hypertension is increased in EURODIAB (particularly for women) compared with EDC, accounting for this does not explain the significant excess of CVD in normoalbuminuria women from EURODIAB for 77% of these cases were normotensive.
The major difference between the risk factor patterns in the two populations is in terms of glycaemic control. While in men in both populations, GHb is marginally increased in those with CVD (as one would expect given its dear relationship to renal disease and CVD risk factors), this is only true for women in EDC where the relationship reaches significance (P < 0.05). In EURODIAB women, however, the relationship is equally strong but in the opposite direction. As this is a cross-sectional data set, it is possible that the true assodation is indeed positive and that in Europe (and to a lesser extent in Pittsburgh), subsequent to developing CVD, the affeaed patients improved their glycaemic control, perhaps stimulated to do so by knowledge of their CVD status. While we do not have historical data to examine this potential explanation, we did review data concerning the frequency of insulin injections. As this did not vary by CVD status, this analysis neither supports nor negates the hypothesis. Interestingly, this inverse assodation is not seen in the whole EURODIAB cohort. 3 While it is, thus, uncertain why the inverse assodation between CVD and HbA, c is seen in EURODIAB women, it is dear that glycaemic control is not a major predictor in either population and does not enter any of the final male models. These observations are further confirmed by the Pittsburgh prospective data in which baseline GHb provided no prediction of CHD over the ensuing 4 years. 4 Future comparisons of these two cohorts using prospective data (currently being collected in EURODIAB) will be of great interest.
In conclusion, this comparison has shown relatively similar CVD rates in populations in Europe compared to the Pittsburgh area of the US. Given the excess of macroalbuminuria in the Pittsburgh population, higher rates there might have been anticipated as renal disease has been reported to be a major risk factor. Interestingly, the European women explain this contradiction by displaying an excess prevalence of CVD in the absence of renal disease (not fully explained by any risk factor) and a relatively weak link between CVD and renal disease. Furthermore, European women showed an excess of CVD in the lowest quartile of HbA lc , a difference which was only partially explained by a stronger association with lipid and blood pressure disturbances.
Further follow-up and comparisons of these populations may hopefully shed more light on the continuing controversy as to the pathogenic role of glycaemic control and other factors in diabetic macrovascular disease.
